Individualized antibiotic therapy in patients with ventilator-associated pneumonia

• Published in: Journal of medical microbiology Vol. 66; no. 1; pp. 78 - 82
• Main Authors: Yilmaz, Gürdal, Salyan, Sedat, Aksoy, Firdevs, Köksal, İftihar
• Format: Journal Article
• Language: English
• Published: England 01.01.2017
• Subjects: Acinetobacter baumannii - drug effects; Acinetobacter baumannii - isolation & purification; Adult; Aged; Anti-Bacterial Agents - therapeutic use; C-Reactive Protein - metabolism; Calcitonin - blood; Enterobacter cloacae - drug effects; Enterobacter cloacae - isolation & purification; Escherichia coli - genetics; Escherichia coli - isolation & purification; Female; Fever - drug therapy; Humans; Intensive Care Units; Klebsiella pneumoniae - drug effects; Klebsiella pneumoniae - isolation & purification; Male; Middle Aged; Oxygen - blood; Pneumonia, Ventilator-Associated - diagnosis; Pneumonia, Ventilator-Associated - drug therapy; Pneumonia, Ventilator-Associated - microbiology; Prospective Studies; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - isolation & purification; Serratia marcescens - drug effects; Serratia marcescens - isolation & purification; Staphylococcus aureus - drug effects; Staphylococcus aureus - isolation & purification

The optimal duration of the treatment of ventilator-associated pneumonia (VAP) is still the subject of debate. While 1 week treatment has been reported as possibly sufficient, patients generally receive antibiotic therapy for 10 to 14 days. The purpose of our study was to investigate whether length...